Omega Therapeutics, Inc. OMGA
Set alert
0.14 USD 0.00 0.00%
At close · Feb 24
0.1426 Day range 0.166
0.75 52-week range 6.30
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.166
- Prev close
- 0.1426
- Mkt cap
- 44.90M
- Vol
- 4.28M
- Avg vol
- 315.41K
- EPS
- -1.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1426
- High
- 0.166
- Forward P/E
- -0.89
- Beta
- 1.84
- Short ratio
- 16.34
- Inst. own
- 90.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 1.00
- 200-d avg
- 1.82
- 1y target
- 9.50
Analyst view
Consensus: none
Price target (mean) 9.50 +6562.0% upside
Now 0.1426
- Target (low)
- 4.00
- Target (mean)
- 9.50
- Target (high)
- 12.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.26333 | -0.31 – -0.17 | -0.37 | +28.8% | 1.12M | +13.3% | 6 |
| Next quarter | -0.2675 | -0.30 – -0.23 | -0.36 | +25.7% | 866.17K | -63.3% | 4 |
| Current year | -1.22 | -1.38 – -0.98 | -1.80 | +32.0% | 8.53M | +175.8% | 6 |
| Next year | -1.03 | -1.28 – -0.55 | -1.22 | +16.2% | 2.90M | -66.0% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 7, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jun 18, 2024 | Raymond James | Initiated | — | Outperform |
| May 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 7, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Apr 30, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 1, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jan 4, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 13, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 10, 2023 | Wedbush | Maintained | Outperform | Outperform |
| Sep 1, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 4, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 8, 2023 | Chardan Capital | Reiterated | — | Buy |
| Mar 31, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 24, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 10, 2023 | JonesTrading | Initiated | — | Buy |
| Mar 3, 2023 | Piper Sandler | Maintained | — | Overweight |
| Dec 8, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Sep 23, 2022 | Chardan Capital | Initiated | — | Buy |
| May 24, 2022 | Goldman Sachs | Maintained | — | Neutral |
| May 23, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 24, 2021 | Wedbush | Initiated | — | Outperform |
| Aug 24, 2021 | Jefferies | Initiated | — | Buy |
| Aug 24, 2021 | Piper Sandler | Initiated | — | Overweight |
| Aug 24, 2021 | Goldman Sachs | Initiated | — | Neutral |